Anthony Hyman

Founder & Board Member at Dewpoint Therapeutics

Tony Hyman’s research has played a central role in defining the emergent area of phase separation and biomolecular condensates. He is currently Director and Group Leader at the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG). His lab has a long history of studying cell polarity, spindle assembly, and positioning, and microtubule dynamics, and today is focused on understanding how cells form non-membrane bound compartments.

Hyman started his career in postdoctoral research in the lab of Tim Mitchison at the University of California, investigating the mechanism of chromosome movement studied in vitro. In 1993, Tony became Group Leader at the European Molecular Biology Laboratory in Heidelberg, before he moved to Dresden in 1999 as a founding director of the MPI-CBG. In 2002 he was named honorary Professor of Molecular Cell Biology at Dresden University of Technology. He has won numerous prizes, including the EMBO Gold Medal, the Leibnitz Prize, and the Schleiden Medal. He received his BSc first class in zoology from the University College in London in 1984 and completed his Ph.D. in 1987 under the supervision of Dr. John White at the Laboratory of Molecular Biology, MRC in Cambridge, England.

Location

Dresden, Germany

Links


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


Dewpoint Therapeutics

Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions has pathways that are regulated by condensates or arise from the dysfunction of condensates - including cancer, neurodegeneration, and metabolic disease.


Employees

51-200

Links